The deal is giving Moderna 176 million dollars ... Do you have a photo or video of a breaking news story? Send it to us here ...
CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. Learn ...
As fears of a pandemic mount, the biotech company’s mRNA vaccine trial is set to release Phase 1/2 results later this year, ...
The deal "puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline," said ...
CureVac NV, a German biopharma company with its U.S. headquarters in Boston, is restructuring after signing a licensing deal ...
Following the announcement of the deal, CureVac said it would lay off 30% of its staff as part of a strategic restructuring.
GSK reached a licensing agreement with mRNA-vaccine developer CureVac worth up to $1.8 billion to develop its vaccines for ...
Results from Moderna’s early studies of the bird flu shot are expected in the next few weeks. The U.S. government contract is ...
CIDRAP: HHS Awards Moderna $176 Million To Develop MRNA H5 Avian Flu Vaccine The US Department of Health and Human Services ... Flu Vaccine Rights In Up To $1.56 Billion Deal GSK struck a deal to buy ...
The first large trial of a COVID and flu vaccine combo suggests it boosts immune protection even more than single-target ...
Vaccine rival Moderna inked a deal to secure $176 million in U.S. government funding on Tuesday to test avian flu vaccines in ...
The duo have an existing collaboration, but the latest deal will give GSK the chance to develop potential flu and Covid-19 ...